Acromegaly and Gigantism Market - Forecast(2024 - 2030)

Acromegaly and Gigantism Market size is estimated to reach $2.3 billion by 2027, growing at a CAGR of 4.1% during the forecast period 2022-2027. Gigantism and acromegaly are syndromes of surplus discharge of growth hormone (hypersomatotropism) that are almost regularly owing to a pituitary adenoma. Prior to the closing of the epiphyses, the outcome is gigantism. Subsequently, the outcome is acromegaly, which brings about different facial and additional features. Acromegaly is brought about by when the pituitary gland (a tiny endocrine gland tied to the bottom of the brain), produces excessive growth hormone. Investigations on the efficiency of pegvisomant monotherapy in acromegaly have indicated that pegvisomant monotherapy, conducted either as primary medical therapy or as adjunctive therapy as per provincial routine, resulted in IGF-1 normalization in greater than 75% of patients. Furthermore, pegvisomant monotherapy had a supportive security profile, constant with former findings, and potential data are required to further assess the function of primary pegvisomant monotherapy in acromegaly. The increasing investments in R&D for developing new molecules and the advancement of a new therapy for treatment like novel approaches in monotherapy are set to drive the Acromegaly and Gigantism Market. The rising hormonal disorders and potential pipeline medications are set to propel the growth of the Acromegaly and Gigantism Market during the forecast period 2022-2027. This represents the Acromegaly and Gigantism Industry Outlook.

Acromegaly and Gigantism Market Report Coverage

The report: “Acromegaly and Gigantism Market Forecast (2022-2027)”, by Industry ARC, covers an in-depth analysis of the following segments of the Acromegaly and Gigantism Market.

By Therapy: Monotherapy, and Surgery.
By Route Of Administration: Subcutaneous, Intramuscular, Oral, Buccal, Intranasal, Unknown.
By Geography: North America (the U.S, Canada, and Mexico), South America (Brazil, Argentina, Chile, Colombia, Rest of South America), Europe (Germany, France, UK, Italy, Spain, Russia, and Rest of Europe), Asia-Pacific (China, Japan, South Korea, India, Australia & New Zealand, and Rest of Asia-Pacific), and Rest Of The World (Middle East, Africa).

Key Takeaways

• Geographically, North America Acromegaly and Gigantism Market accounted for the highest revenue share in 2021 and it is poised to dominate the market over the period 2022-2027 owing to the building predominance of pituitary tumors bringing about pituitary adenoma resulting in acromegaly and gigantism in the North American region.
• Acromegaly and Gigantism Market growth is being driven by the rising pervasiveness of genetic ailments, pituitary adenoma and altered lifestyle. However, inadequate knowledge regarding the diagnosis and handling of acromegaly and gigantism in developing economies is one of the major factors hampering the growth of the Acromegaly and Gigantism Market.
• Acromegaly and Gigantism Market Detailed Analysis on the Strength, Weakness, and Opportunities of the prominent players operating in the market will be provided in the Acromegaly and Gigantism Market report. 

Acromegaly and Gigantism Market: Market Share (%) by Region, 2021

For More Details on This Report - Request for Sample

Acromegaly and Gigantism Market Segment Analysis – By Therapy

The Acromegaly and Gigantism Market based on therapy can be further segmented into Monotherapy and Surgery. The Monotherapy Segment held the largest market share in 2021. This growth is owing to all the molecules present in the drug pipeline for acromegaly and gigantism being advanced as monotherapy drugs as per the pipeline analysis report. Nearly all the molecules are in the pre-clinical phase of development. Acromegaly and Gigantism occur owing to a pituitary adenoma. There are three kinds of drugs presently utilized to treat acromegaly namely dopamine agonists, somatostatin analogs, and growth hormone receptor antagonists. The increased application of cabergoline monotherapy to normalize IGF-I levels in greater than one-third of patients with acromegaly is further propelling the growth of this segment.

Furthermore, the Monotherapy segment is estimated to grow with the fastest CAGR of 4.9% during the forecast period 2022-2027 owing to the increased application of pegvisomant is a safe option of monotherapy and the most efficient treatment of acromegaly as both a monotherapy and in integration with somatostatin analogues to date.

Acromegaly and Gigantism Market Segment Analysis – By Route Of Administration

The Acromegaly and Gigantism Market based on the route of administration can be further segmented into Subcutaneous, Intramuscular, Oral, Buccal, Intranasal, and Unknown. The Subcutaneous Segment held the largest market share in 2021. This growth is owing to the direct transfer of the drug into the layer of skin below the dermis and epidermis. Acromegaly and gigantism are caused by a pituitary adenoma. The effortless mode of administration and need for minimum skills is further propelling the growth of this segment.

Furthermore, the Intramuscular segment is estimated to grow with the fastest CAGR of 5.2% during the forecast period 2022-2027 owing to the surging injection of molecules directly into the muscles which will have a greater direct impact on the target cells. Sandostatin LAR is injected through the intramuscular route of administration for the treatment of Acromegaly caused by a pituitary adenoma. Medical treatment for gigantism includes somatostatin analog (Octreotide, Lanreotide) injections. These kinds of developments are further propelling the growth of the Intramuscular segment.

Acromegaly and Gigantism Market Segment Analysis – By Geography

The Acromegaly and Gigantism Market based on geography can be further segmented into North America, Europe, Asia-Pacific, South America, and the Rest of the World. North America (Acromegaly and Gigantism Market) held the largest share with 33% of the overall market in 2021. The growth of this region is owing to the increasing predominance of pituitary adenoma and surging research activities. The endeavors of key players in establishing novel and effective drug pipelines are fuelling the local demand for the Acromegaly and Gigantism Market. The progressive treatment methods, supportive reimbursement policies, and establishment of new products are further propelling the growth of the Acromegaly and Gigantism Market in the North American region.

Furthermore, the Asia-Pacific region is estimated to be the region with the fastest CAGR rate over the forecast period 2022-2027. This growth is owing to factors like proliferating population and expanding predominance of diabetes and pituitary adenoma. Furthermore, Sun Pharma and WOCKHARDT are emerging with novel formulations for octreotide molecules which is thought to be present in the pre-clinical phase. The authorization of these formulations is estimated to propel the growth of the Acromegaly and Gigantism Market in the Asia-Pacific region.

Acromegaly and Gigantism Market - Drivers

Excessive Secretion Of Growth Hormone And Genetic Causes Are Projected To Drive The Growth Of Acromegaly and Gigantism Market:

Gigantism and acromegaly are hormonal disorder syndromes brought about by excessive secretion of growth hormone, a condition termed hypersomatotropism. The two syndromes mainly happen to owe to a pituitary adenoma. Gigantism happens prior to the closing of epiphyses and acromegaly happens consequent to the closing of epiphyses and outcome in different unique facial and additional features. Both gigantism and acromegaly are birth defects and are very comparable to each other. However, the singular difference is the span of time in which they happen. Gigantism frequently happens at the time of childhood and acromegaly materializes in adulthood. Acromegaly in adults normally happens between the ages of 30 and 50. It happens consequence of the fusion of growth plate cartilage in adulthood. It has been discovered over the former twenty years that there are numerous genetic causes of pituitary gigantism and acromegaly inclusive of multiple endocrine neoplasia type 1 and 4, McCune-Albright syndrome, Carney complex, familial isolated pituitary adenoma, currently recognized X-linked acrogigantis, and more. The surplus secretion of growth hormone and genetic causes are therefore fuelling the growth of the Acromegaly and Gigantism Market during the forecast period 2022-2027.

Development Of Innovative Medications Is Expected To Boost The Demand Of Acromegaly and Gigantism:

Acromegaly and gigantism are unique endocrinopathies that are expressed by high serum levels of growth hormone (GH), which is frequently secreted by the adenoma of the anterior pituitary gland. Presently, the only curative treatment alternative for acromegaly is transsphenoidal surgery. Patients who are not good candidates for surgery involve people whose causative tumors are ectopic or prolong into the cavernous sinus where pharmacotherapy may be utilized to handle patients. Novartis’ Sandostatin (octreotide acetate) was the earliest somatostatin analog to acquire approval in the U.S. market and turned accessible to patients in 1988. Chiasma’s Mycapssa (octreotide acetate) turned into the earliest oral somatostatin analog to be introduced for the treatment of acromegaly in the U.S. in 2020. These kinds of innovative medications are driving the growth of the Acromegaly and Gigantism Market during the forecast period 2022-2027.

Acromegaly and Gigantism Market – Challenges

Detection Of Acromegaly And Development Of No Particular Drugs For Gigantism Are Challenging The Growth Of The Acromegaly and Gigantism Market:

Acromegaly is a slow, advancing condition. It consumes its time to injure the body of the person secretly, and therefore, it is hard to diagnose at the time of the commencing years. Usually, it takes 10-12 years to diagnose from the point of the outset of symptoms. The alterations that happen in the body are so gradual that even specialists stay unaware of them. It is thus difficult to discover Acromegaly. The symptoms emerge so gradually, that by the time acromegaly is diagnosed, health issues like related cardiovascular, cerebrovascular, and respiratory ailments and malignancies start to establish. This is why mortality rates owing to acromegaly are soaring. No drugs are being particularly established for gigantism which means that certain pipeline agents will not acquire advantage from being utilized to treat pediatric patients. These issues are hampering the growth of the Acromegaly and Gigantism Market.

Acromegaly and Gigantism Industry Outlook

Development of cost-effective and powerful drug molecules for the treatment of acromegaly and gigantism, discontinuation of drug molecules, mergers and acquisitions, collaborations, and partnerships are key strategies adopted by players in the market. Acromegaly and Gigantism top 10 companies include:

1. Amryt Pharma Plc
2. Aquestive Therapeutics
3. Camurus
4. Xeris Pharmaceuticals (Strongbridge Biopharma)
5. Pfizer Inc.
6. Teijin Pharma Limited
7. Novartis AG
8. Crinetics Pharmaceuticals
9. Ionis Pharmaceuticals Inc.
10. Midatech Pharma Plc

Acquisitions/Product Launches:

• In October 2021, Xeris Pharmaceuticals, Inc. (“Xeris”), declared that it has favorably finished the formerly declared acquisition of Strongbridge Biopharma plc. Under the terms of the acquisition agreement, the companies of Xeris and Strongbridge are presently integrated under Xeris Biopharma Holdings, Inc. (“Xeris Biopharma Holdings”). Strongbridge shares and Xeris shares concluded trading on the Nasdaq Global Select Market (“Nasdaq”) at the termination of business. Shares of Xeris Biopharma Holdings were anticipated to commence trading on the Nasdaq under the ticker symbol “XERS” on October 6, 2021.
  

• In October 2021, Crinetics Pharmaceuticals, Inc. in conjunction with 5 AM Ventures and Frazier Healthcare Partners, declared the composition of a self-reliant operated novel company, Radionetics Oncology. Radionetics targets to establish a deep pipeline of new, targeted, nonpeptide radiopharmaceuticals for the healing of extensive series of oncology indications. Radionetics’ pipeline is based on an expansive permissive platform and intellectual property that will influence more than a decade of discovery knowledge within Crinetics.

• In July 2021, Aquestive Therapeutics, Inc. declared that the U.S. Food and Drug Administration (FDA) has approved for registering the resubmission of the New Drug Application (NDA) for Libervant™ (diazepam) Buccal Film for the administration of seizure clusters. The FDA has determined a Prescription Drug User Fee Act (“PDUFA”) target goal date of December 23, 2021. Aquestive accepted a Complete Response Letter (CRL) from the FDA in September 2020, finished a Type A meeting with the FDA in November 2020, and acquired further counseling from the FDA in February 2021.

Related Reports:

Acromegaly Treatment Market

Report Code: HCR 36376

Thyroid Gland Disorder Treatment Market

Report Code: HCR 58284

For more Lifesciences and Healthcare Market reports, please click here